Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology, immunology, and critical care therapies, announced today the U.S. launch of CAMCEVI™ (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults. Accord BioPharma is heading distribution in the U.S. The U.S. Food and Drug Administration approved…

eTurboNews izindatshana ezababhalisi kuphela. Ukubhalisa kuyinto MAHHALA.
Ababhalisile bangena lapha Chofoza lapha ukuze ubhalise MAHHALA

LOKHO ONGAKUTHATHE KULESI SIHLOKO:

focused on development of oncology, immunology, and critical care therapies, announced today the U.
Accord BioPharma is heading distribution in the U.
launch of CAMCEVI™ (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults.